Potentiating cancer vaccine efficacy in liver cancer
Hepatocellular carcinoma (HCC) is the most common liver malignancy with a poor prognosis and an overall 5-year survival rate of approximately 5–6%. This is due because standard of care treatment options are limited and none of them shows a sufficient efficacy. HCC is an “inflammation-induced cancer”...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-10-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1488564 |